What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Melanoma, Ipilimumab, Immunology and Surgery.
As part of his studies on Internal medicine, he often connects relevant subjects like Oncology.
His Melanoma research is multidisciplinary, incorporating elements of Survival rate and Blockade.
In his research on the topic of Ipilimumab, Carboplatin is strongly related with Interim analysis.
His work in Immunology addresses issues such as Cancer, which are connected to fields such as Mutation and Gene expression profiling.
His Surgery research is multidisciplinary, relying on both Gastroenterology, Placebo and Hazard ratio.
His most cited work include:
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. (10003 citations)
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (8133 citations)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Melanoma, Oncology, Ipilimumab and Immunology.
His research links Surgery with Internal medicine.
His studies in Surgery integrate themes in fields like Placebo, Cohort and Hazard ratio.
His work focuses on many connections between Melanoma and other disciplines, such as Immunotherapy, that overlap with his field of interest in CTLA-4.
F. Stephen Hodi has researched Oncology in several fields, including Pembrolizumab, Progressive disease and Advanced melanoma.
F. Stephen Hodi combines subjects such as Vemurafenib, Phases of clinical research, Clinical endpoint, Randomized controlled trial and Combination therapy with his study of Ipilimumab.
He most often published in these fields:
- Internal medicine (49.61%)
- Melanoma (44.31%)
- Oncology (38.04%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (49.61%)
- Melanoma (44.31%)
- Oncology (38.04%)
In recent papers he was focusing on the following fields of study:
F. Stephen Hodi mainly focuses on Internal medicine, Melanoma, Oncology, Cancer research and Immunotherapy.
Ipilimumab, Nivolumab, Adverse effect and Cancer are the subjects of his Internal medicine studies.
His study focuses on the intersection of Nivolumab and fields such as Progressive disease with connections in the field of Lung cancer.
The Melanoma study combines topics in areas such as Clinical trial, Tolerability, Randomized controlled trial, Antigen and Toxicity.
His Oncology research incorporates elements of Pembrolizumab, Atezolizumab and Clinical endpoint.
His Cancer research research incorporates themes from Cytotoxic T cell, T cell, Immune system and Blockade.
Between 2018 and 2021, his most popular works were:
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. (322 citations)
- Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab (149 citations)
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. (110 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
F. Stephen Hodi mainly investigates Internal medicine, Oncology, Melanoma, Cancer research and Immunotherapy.
His research integrates issues of Immune checkpoint, Cancer, Nivolumab and Pembrolizumab in his study of Oncology.
The concepts of his Melanoma study are interwoven with issues in Interleukin 6, Ipilimumab, Antigen and Atezolizumab.
F. Stephen Hodi performs multidisciplinary study in the fields of Ipilimumab and In patient via his papers.
F. Stephen Hodi interconnects Immune checkpoint inhibitors, Immune system, Single agent, Acute-phase protein and Cytotoxic T cell in the investigation of issues within Cancer research.
His Immunotherapy research includes elements of Metastatic melanoma, Response criteria, Drug toxicity and Pneumonitis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
